VC-backed Infraredx sets IPO pricing terms

Burlington, Massachusetts-based Infraredx, a cardiovascular imaging firm, has priced its IPO of 4 million shares at between $13 and $15 a share. The stock will trade on the NASDAQ under the ticker symbol “REDX.” RBC Capital Markets LLC Canaccord Genuity Inc and BMO Capital Markets Corp are serving as lead underwriters. Its backers include Sanderling Ventures, Nipro Corp. and Eastwood Capital.

PRESS RELEASE

BURLINGTON, MASS. — Infraredx, Inc., a cardiovascular imaging company advancing the diagnosis and treatment of coronary artery disease, announced that today it launched a road show for its initial public offering (“IPO”). Infraredx is offering 4.0 million shares of its common stock, and underwriters will have a 30-day option to buy an additional 600,000 shares. The IPO price is currently expected to be between $13.00 and $15.00 per share, and the shares are expected to trade on the NASDAQ Global Market under the symbol, “REDX.”

RBC Capital Markets, LLC, Canaccord Genuity Inc. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. and BTIG, LLC are acting as co-managers for the offering.

This offering is made only by means of a prospectus. When available, a copy of the preliminary prospectus related to the offering can be obtained by contacting RBC Capital Markets, Attention: Prospectus Department, Three World Financial Center, 200 Vesey Street 8th Floor, New York, NY 10281, or by phone at (877) 822-4089 or by emailing equityprospectus@rbccm.com; Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, or by phone at (617) 371-3900, or by emailing prospectus@canaccordgenuity.com; or BMO Capital Markets Corp., at BMO Capital Markets Corp., Attention: Prospectus Department, 3 Times Square, 27th Floor, New York, New York 10036; or by phone at (800) 414-3627 or by emailing bmoprospectus@bmo.com.

A Form S-1 registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Infraredx, Inc.
Infraredx, Inc. is a cardiovascular imaging company advancing the diagnosis and treatment of coronary artery disease, the world’s leading cause of death according to the World Health Organization. Our dual-modality TVC Imaging System™ integrates near-infrared spectroscopy with intravascular ultrasound and is designed to provide physicians with information that has the potential to improve patient clinical outcomes through more tailored treatments. Founded in 1999, Infraredx is headquartered in Burlington, Massachusetts.